Senti Biosciences Holdings, Inc. Income Statement
SNTI|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
Senti Biosciences Holdings, Inc. reported $0 in revenue and $53M in net loss for FY2025. Revenue has declined at a 3.7% compound annual rate over the past 2 years.
Based on SEC 10-K filings.
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -3.15 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $0 | $2.6M | $4.3M | $2.8M |
| SG&A Expense | $26.4M | $37.2M | $38.2M | $21.3M |
| R&D Expense | $34.4M | $32.1M | $28.1M | $22.0M |
| Operating Income | -$61.0M | -$92.7M | -$62.1M | -$40.4M |
| Income Tax | $0 | - | - | - |
| Net Income | -$52.8M | -$71.1M | -$58.2M | -$55.3M |
| EPS (Basic) | -$12.03 | -$16.01 | -$2.23 | -$19.00 |
| EPS (Diluted) | -$12.03 | -$16.01 | -$2.23 | -$19.00 |
| Shares Outstanding | 4.8M | 4.6M | 43.4M | 3.0M |
| Operating Margin | - | -3620.7% | -1448.5% | -1464.9% |
| Profit Margin | - | -2774.6% | -1358.1% | -2003.6% |